Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment

被引:7
作者
Yu, Hongjie [1 ]
Shi, Zhuqing [1 ]
Lin, Xiaoling [2 ]
Bao, Quanwa [3 ]
Jia, Haifei [2 ]
Wei, Jun [1 ]
Helfand, Brian T. [1 ]
Zheng, Siqun. L. [1 ]
Duggan, David [4 ]
Lu, Daru [3 ]
Mo, Zengnan [5 ]
Xu, Jianfeng [1 ,2 ]
机构
[1] NorthShore Univ HealthSyst, Program Personalized Canc Care, 1001 Univ Pl, Evanston, IL 60201 USA
[2] Fudan Univ, Huashan Hosp, Fudan Inst Urol, Shanghai, Peoples R China
[3] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China
[4] City Hope Natl Med Ctr, Translat Genom Res Inst, Phoenix, AZ USA
[5] Guangxi Med Univ, Ctr Genom & Personalized Med, Nanning, Guangxi Zhuang, Peoples R China
关键词
clinical validity; genetic risk score; prostate cancer; GENOME-WIDE ASSOCIATION; MEN; PREDICTION; VARIANTS; BIOPSY;
D O I
10.1002/pros.23920
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Several polygenic risk score (PRS) methods are available for measuring the cumulative effect of multiple risk-associated single nucleotide polymorphisms (SNPs). Their performance in predicting risk at the individual level has not been well studied. Methods We compared the performance of three PRS methods for prostate cancer risk assessment in a clinical trial cohort, including genetic risk score (GRS), pruning and thresholding (P + T), and linkage disequilibrium prediction (LDpred). Performance was evaluated for score deciles (broad-sense validity) and score values (narrow-sense validity). Results A training process was required to identify the best P + T model (397 SNPs) and LDpred model (3 011 362 SNPs). In contrast, GRS was directly calculated based on 110 established risk-associated SNPs. For broad-sense validity in the testing population, higher deciles were significantly associated with higher observed risk;P(trend)was 7.40 x 10(-11), 7.64 x 10(-13), and 7.51 x 10(-10)for GRS, P + T, and LDpred, respectively. For narrow-sense validity, the calibration slope (1 is best) was 1.03, 0.77, and 0.87, and mean bias score (0 is best) was 0.09, 0.21, and 0.10 for GRS, P + T, and LDpred, respectively. Conclusions The performance of GRS was better than P + T and LDpred. Fewer and well-established SNPs of GRS also make it more feasible and interpretable for genetic testing at the individual level.
引用
收藏
页码:83 / 87
页数:5
相关论文
共 50 条
[41]   External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series [J].
Loeb, Stacy ;
Carvalhal, Gustavo F. ;
Kan, Donghui ;
Desai, Angel ;
Catalona, William J. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2012, 30 (05) :584-589
[42]   Comparative analysis of three risk assessment tools in Australian patients with prostate cancer [J].
Tamblyn, David J. ;
Chopra, Samarth ;
Yu, Changhong ;
Kattan, Michael W. ;
Pinnock, Carole ;
Kopsaftis, Tina .
BJU INTERNATIONAL, 2011, 108 :51-56
[43]   Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy [J].
Leapman, Michael S. ;
Ameli, Niloufar ;
Shinohara, Katsuto ;
Nguyen, Hao G. ;
Meng, Maxwell V. ;
Cooperberg, Matthew R. ;
Carroll, Peter R. .
CLINICAL GENITOURINARY CANCER, 2017, 15 (01) :93-99
[44]   Risk assessment for colorectal cancer via polygenic risk score and lifestyle exposure: a large-scale association study of East Asian and European populations [J].
Xin, Junyi ;
Du, Mulong ;
Gu, Dongying ;
Jiang, Kewei ;
Wang, Mengyun ;
Jin, Mingjuan ;
Hu, Yeting ;
Ben, Shuai ;
Chen, Silu ;
Shao, Wei ;
Li, Shuwei ;
Chu, Haiyan ;
Zhu, Linjun ;
Li, Chen ;
Chen, Kun ;
Ding, Kefeng ;
Zhang, Zhengdong ;
Shen, Hongbing ;
Wang, Meilin .
GENOME MEDICINE, 2023, 15 (01)
[45]   External Validation of the Cancer of the Prostate Risk Assessment Score to Predict Biochemical Relapse after Radical Prostatectomy for Prostate Cancer in Japanese Patients [J].
Yoshida, Takahiro ;
Nakayama, Masashi ;
Takeda, Ken ;
Arai, Yasuyuki ;
Kakimoto, Ken-ichi ;
Nishimura, Kazuo .
UROLOGIA INTERNATIONALIS, 2012, 89 (01) :45-51
[46]   A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score [J].
Yamaguchi, Yuichiro ;
Hayashi, Yujiro ;
Ishizuya, Yu ;
Takeda, Ken ;
Nakai, Yasutomo ;
Arai, Yasuyuki ;
Nakayama, Masashi ;
Kakimoto, Ken-ichi ;
Nishimura, Kazuo .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (02) :197-201
[47]   Performance of Current Thromboembolism Risk Assessment Tools in Patients With Gastric Cancer and Validity After First Treatment [J].
Fuentes, Harry E. ;
Paz, L. H. ;
Wang, Y. ;
Oramas, D. M. ;
Simons, C. R. ;
Tafur, A. J. .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2018, 24 (05) :790-796
[48]   Comparison of Fracture Risk Assessment Tool Score to Bone Mineral Density for Estimating Fracture Risk in Patients With Advanced Prostate Cancer on Androgen Deprivation Therapy [J].
James, Herbert, III ;
Aleksic, Ilija ;
Bienz, Marc Nicolas ;
Pieczonka, Christopher ;
Iannotta, Peter ;
Albala, David ;
Mariados, Neil ;
Mouraviev, Vladimir ;
Saad, Fred .
UROLOGY, 2014, 84 (01) :164-168
[49]   Assessment of Diagnostic Performance of Risk Factors Affecting Extraprostatic Extension: Role of Zonal Level of Prostate Cancer [J].
Park, Seo Young ;
Jeon, Ga young .
CURRENT MEDICAL IMAGING, 2024, 20
[50]   Validation of the prognostic value of a three-gene signature and clinical parameters-based risk score in prostate cancer patients [J].
Saemundsson, Arni ;
Xu, Li-Di ;
Meisgen, Florian ;
Cao, Rong ;
Ahlgren, Goran .
PROSTATE, 2023, 83 (12) :1133-1140